
OncoSec Medical Incorporated ONCS
Quarterly report 2022-Q3
added 12-15-2022
OncoSec Medical Incorporated Total Non Current Liabilities 2011-2026 | ONCS
Annual Total Non Current Liabilities OncoSec Medical Incorporated
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 6.35 M | 636 K | 1.47 M | 1.14 M | 887 K | - | - | - | 979 K | 1.5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.35 M | 636 K | 1.85 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
5.96 T | $ 18.06 | - | $ 28.2 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 19.44 | -0.46 % | $ 909 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Arena Pharmaceuticals
ARNA
|
52.2 M | - | -6.81 % | $ 3.04 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
Protara Therapeutics
TARA
|
999 K | $ 5.03 | -3.08 % | $ 215 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Tarsus Pharmaceuticals
TARS
|
605 K | $ 67.0 | -0.3 % | $ 2.8 B | ||
|
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Theravance Biopharma
TBPH
|
521 M | $ 14.9 | -1.91 % | $ 750 M | ||
|
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.2 | -6.97 % | $ 306 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
Bio-Techne Corporation
TECH
|
617 M | $ 51.31 | -2.65 % | $ 8.08 B | ||
|
Tenax Therapeutics
TENX
|
64.2 K | $ 14.64 | -2.2 % | $ 574 M | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
299 K | $ 1.07 | -2.29 % | $ 21.9 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
19.4 B | $ 28.76 | -3.43 % | $ 32.9 B | ||
|
Enochian Biosciences
ENOB
|
425 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Equillium
EQ
|
8.33 M | $ 2.03 | -1.46 % | $ 116 M | ||
|
Eton Pharmaceuticals
ETON
|
4.56 M | $ 23.81 | 1.51 % | $ 641 M | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
CRISPR Therapeutics AG
CRSP
|
70.2 M | $ 46.38 | -2.45 % | $ 4.17 B |